PlainPharmaWatch

CMS Open Payments · Tool

Merck KGaA vs Nexxt Spine LLC

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Merck KGaA has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 587, versus 576 for the other company. Its single largest recorded recipient represents 15.4% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Merck KGaA
HHI 587 · top recipient 15.4%
Ranked #1,237 of 1,838 companies by HHI
Nexxt Spine LLC
HHI 576 · top recipient 11.4%
Ranked #1,245 of 1,838 companies by HHI

Payment Overview

Company A

Merck KGaA

Total Payments
$290.6K
% of Industry
0.0%
Transactions
132
Avg per Transaction
$2.2K
Recipients
101
Avg per Recipient
$2.9K
Payment Types
4
Top Payment Type
Consulting Fee
Company B

Nexxt Spine LLC

Total Payments
$292.8K
% of Industry
0.0%
Transactions
358
Avg per Transaction
$817.96
Recipients
358
Avg per Recipient
$817.96
Payment Types
6
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

Merck KGaA vs Nexxt Spine LLC - total reported payments in CMS Open Payments PY2024

Nexxt Spine LLC$292.8KMerck KGaA$290.6K

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Merck KGaA

Consulting Fee $170.1K

59.5%

Travel and Lodging $80.1K

28.0%

Compensation for Services Other Than Consulting $34.2K

12.0%

Food and Beverage $1.3K

0.4%

Nexxt Spine LLC

Royalty or License $185.7K

63.4%

Consulting Fee $45.3K

15.5%

Travel and Lodging $26.1K

8.9%

Food and Beverage $19.0K

6.5%

Compensation for Services Other Than Consulting $15.8K

5.4%

Entertainment $826.62

0.3%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Merck KGaA

  1. 1

    JEREMY SUGARMAN

    $44,080.86 · 17 txns

  2. 2

    LEORAH A FREEMAN

    $22,055.61 · 6 txns

  3. 3

    RILEY BOVE

    $20,450.00 · 4 txns

  4. 4

    HEIDI J CRAYTON

    $20,232.47 · 7 txns

  5. 5

    JONATHAN SCHOENFELD

    $17,447.22 · 4 txns

Nexxt Spine LLC

  1. 1

    Alexander C Lemons

    $33,292.21 · 7 txns

  2. 2

    John W Klekamp

    $29,697.37 · 3 txns

  3. 3

    Theodore Belanger

    $28,970.00 · 1 txns

  4. 4

    Michael J McNamara

    $23,005.16 · 2 txns

  5. 5

    Kamran Parsa

    $19,739.06 · 11 txns

Summary Comparison

Metric Merck KGaA Nexxt Spine LLC
Total Payments $290.6K $292.8K
% of Industry Total 0.0% 0.0%
Transaction Count 132 358
Avg per Transaction $2.2K $817.96
Recipient Count 101 358
Avg per Recipient $2.9K $817.96
Payment Type Count 4 6
Top Payment Type Consulting Fee Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.